21.01.2025.
The buzz around weight loss medications like Wegovy, Ozempic, and Zepbound continues to grow as these drugs promise more than just slimmer waistlines.
Recent research reveals that weight loss drugs could also play a role in addressing conditions such as addiction, blood clotting issues, and even dementia.
But while the benefits are noteworthy, these medications come with risks that patients should consider carefully.
A study published in Nature Medicine analyzed data from over two million diabetes patients in the United States, including more than 216,000 who were prescribed these popular drugs.
Researchers examined how these GLP-1 receptor agonists, originally designed for obesity and type 2 diabetes, impact a wide range of health outcomes—175 in total.
The findings were promising: these medications appear to reduce the risk of various conditions, including Alzheimer’s disease, by 12 per cent.
They also showed potential benefits in lowering the likelihood of alcohol and drug addiction, psychotic disorders like schizophrenia, seizures, and chronic kidney disease.
The drugs’ effects seem to stem not just from weight loss but also from reducing inflammation, improving blood flow, and influencing brain signals related to impulse control.
However, these benefits don’t come without trade-offs.
The study highlighted several adverse effects, including gastrointestinal issues, low blood pressure, fainting, kidney stones, arthritis, and even drug-induced pancreatitis.
The increased risk of low blood pressure and kidney stones may be linked to reduced fluid intake due to appetite suppression, a key feature of these drugs.
As our understanding of obesity evolves, so does the way we evaluate treatments like GLP-1 receptor agonists.
Experts are now moving beyond BMI as a sole indicator of health, focusing instead on weight distribution and how obesity impacts organ function.
This shift in perspective may change how researchers and clinicians assess the effectiveness of these medications.
Another concern is the rise of counterfeit or unregulated versions of these drugs. Reports from Europe, the US, and Brazil highlight the dangers of accessing weight loss treatments through uncontrolled sources, which has led to severe side effects and even fatalities in some cases.
For those considering these medications, the key takeaway is balance. While they offer a range of health benefits, potential side effects and risks should be part of the conversation with healthcare providers.
Weight loss drugs may be reshaping the way we treat obesity, but they are not without their complexities.
